Cogprints
Login | Create Account

Effect of rosiglitazone on inflammatory mediators in type 2 diabetes

Aruliah Sohna Chandra Packiavathy, Marimuthu Ramalingam, Chenniappan Anchana Devi (2010) Effect of rosiglitazone on inflammatory mediators in type 2 diabetes. [Journal (Paginated)]

Full text available as:

[img]
Preview
PDF (Effect of rosiglitazone on inflammatory mediators in type 2 diabetes) - Published Version
Available under License Creative Commons Attribution No Derivatives.
139Kb

Abstract

Type 2 diabetes is a heterogenous disorder involving impairment of both insulin secretion and insulin action. Inflammation is predominantly seen in type 2 diabetes. The effect of rosiglitazone on inflammatory mediators was analysed in the present study. The study groups consisted of 220 type 2 diabetic patients (110 Males, 110 Females) and 220 age and sex matched rosiglitazone treated type 2 diabetic subjects (110 Males, 110 Females). The values of C-reactive protein (CRP), Complement 3 (C3), ceruloplasmin, cortisol, alpha 1 antitrypsin and haptoglobin were found to be significantly decreased by rosiglitazone when compared to type 2 diabetic subjects. The levels of tumour necrosis factor α (TNF-α), interleukin-6 (IL-6) and adiponectin were found to be remarkably reduced in rosiglitazone treated type 2 diabetic subjects as compared to type 2 diabetic patients. Hence rosiglitazone therapy serves as an effective approach in restoring immune status in type 2 diabetes mellitus.

Item Type:Journal (Paginated)
Keywords:Rosiglitazone, type 2 diabetes mellitus, inflammation, mediators.
Subjects:JOURNALS
ID Code:7109
Deposited By:International Journal of Biological and Medical Research , (IJBMR) ISSN:0976-6685
Deposited On:22 Nov 2010 14:20
Last Modified:11 Mar 2011 08:57

References in Article

Select the SEEK icon to attempt to find the referenced article. If it does not appear to be in cogprints you will be forwarded to the paracite service. Poorly formated references will probably not work.

[1] Defronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. Diabetes care. 1992; 15(suppl 3):318-368.

[2] Sirtori CR, Agradi E, Conto F, Mantero O, Gotti E. Soyabean protein diet in the treatment of type 2 hyperlipoproteinemia. Lancet. 1977; 1:275-277.

[3] Desvergne B, Wahl WN. Peroxisome proliferator activated receptors: nuclear control of metabolism. Endocr. Rev. 1999; 20:1649-688.

[4] Singer JM, Plot CM, Parker M, Elster SK. Ame. J. Civil. Patha. 1967; 28:611.

[5] Noel R, Rose, Robert M, Nakamura, Clifford Lane H, James D, Folds, Everly C, De Macario. Manual of Clinical Laboratory Immunology. Third edition. 1986. p 183.

[6] Levy AP, Friedenberg P, Loten R, Vita JA, Benjamin EJ. Haptoglobin phenotype and prevalent coronary heart disease in the Framingham offspring cohort. Atherosclerosis. 2004; 172:361-365.

[7] Arakawa H, Maeda M, Tsuji A. Anal. Biochem. 1979; 97:278.

[8] Ravin HA. Improved colormetric enzymatic ceruloplasmin assay. J. Lab. Clin. Med. 1961; 85:161.

[9] Bou Gharious G, Wells DJ, Lu QL, Morgan JE, Partirdge T. Differential expression and secretion of alpha-1- antitrypsin between direct DNA injection and implantation of transfected myoblast. Gene therapy. 1999; 6:1021-1029.

[10] Kuleryyski A. Allergy clin Immunol. 1981; 68:5

[11] Pannacciulli N, Bunt JC, Ortega E, Funahashi T, Salbe A, Bogardus C, Krakoff J. Lower total fasting plasma adiponectin concentrations are associated with higher metabolic rates. J. Clin. Endocrinol. Metab. 2006; 91:1600-1603.

[12] Muller S, Martin S, Koenig W, Hanif I, Moghaddam P, Rathamann W, Haastert B, Gian G, Illig I, Thorand B, Kolb H. Impaired glucose tolerance is associated with increased serum concentrations of interleukin-6 and coagulated acute phase proteins but not TNF-α or its receptors. Diabetologia. 2003; 45:805-812.

[13] Pradhan A, Manson J, Rifai N, Buling R. C-reactive protein, Inter leukin-6 and risk of developing type 2 diabetes mellitus. JAMA. 2001; 286:327-334.

[14] Ritchie RF, Palomaki GE, Neveux LM, Navolotskaria O, Ledue TB, Craig, WY. Reference distributions for complement proteins C3 and C4, a practical, simple and clinically relevant approach in a large cohort study. J. Clin. Lab. Aval. 2004; 98:1-8.

[15] Walter RM, Urlu-Hare M, Lewis-olm K, Oster MH, Arawalt BD, Critchfield JW, Keen CC. Copper, Zinc, Magnesium and manganese status and complications of diabetes mellitus. Diabetes care. 1991; 14:1050-1056.

[16] Castell JV, Gomez-Lechon MJ, David M, Andus T, Geiger T, Trullenque R, Fabra R, Heinrich PC. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS. Lett. 1989; 242:234-239.

Metadata

Repository Staff Only: item control page

Cogprints is powered by EPrints 3 which is developed by the School of Electronics and Computer Science at the University of Southampton. More information and software credits.